

## ABSTRACT TEMPLATE for Company Presentations

- **Investment Rational**

Pioneering computational design of human antibodies to develop smart therapeutic solutions for multiple diseases. BioLogic's most advanced antibody is in phase 1/2 study, showing preclinical data of complete tumor elimination. BioLogic also signed partnerships with Top pharma e.g. Lilly and AstraZeneca. BioLogic's strong leadership team brings in experience from top pharma and top tech companies, and stellar advisors.

- **Business Strategy**

Leveraging its platform, BioLogic is developing a highly differentiated pipeline focusing on validated targets in oncology and immune diseases and entering high value collaborations.

Over the next few years BioLogic is planning to advance clinical development of several fully owned assets creating significant value inflection. Furthermore, existing and new partnerships are expected to generate significant short- and long-term revenues.

- **Core Technology**

BioLogic has a **unique combination of proprietary algorithms and proprietary data** aimed at **designing novel antibodies enabled solely by its technology**. BioLogic is not trying to make traditional antibodies faster and cheaper but rather create antibodies with novel capabilities. This enables BioLogic's therapeutics to be significantly differentiated while focusing on validated targets and reducing significant risk.

- **Product Profile/Pipeline**

BioLogic's pipeline is comprised of unique therapeutics, fully owned or in partnership, enabled by its AI platform. These include BioLogic's lead programs i.e. a dual specific antibody targeting IL13/TSLP for atopic dermatitis and potentially asthma which is anticipated to start phase 1 in 2023 and other programs with best in class potential.

- **What's Next?**

BioLogic is continuously initiating new revolutionary programs while advancing its pipeline and fortifying its AI platform. BioLogic plans to expand its presence and leadership in Boston to scale up its drug development capabilities. Currently BioLogic is raising capital to advance its pipeline to the clinic, enhance the computational platform and expand the US presence.